NTLA-2001 for cardiomyopathies

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 13 Nov 2023: Trial registered, NCT06128629
  2. 13 Dec 2023: Trial started, NCT06128629

The trials

NCT04601051: Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)

State
Completed
Phase
Phase 1
People
72 taking part
Started
5 Nov 2020
Primary completion
12 Sep 2025
Arms
Polyneuropathy Part 1: NTLA-2001, Polyneuropathy Part 2: NTLA-2001, Cardiomyopathy Part 1 (UK only): NTLA-2001, Cardiomyopathy Part 2 (UK only): NTLA-2001, Polyneuropathy Follow-on Dosing (PN Part 1 Dose Level 1 Subjects only): NTLA-2001
Results
None posted
  1. 23 Oct 2020: Trial registered
  2. 5 Nov 2020: Trial started
  3. 12 Sep 2025: Trial completed

NCT06128629: MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

State
Under way
Phase
Phase 3
People
1,200 planned
Started
13 Dec 2023
Primary completion
Dec 2027
Arms
NTLA-2001
Results
None posted
  1. 13 Nov 2023: Trial registered
  2. 13 Dec 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.